Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover

The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers

JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr

The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26

JB Pharma Q2 PAT up 19 % at Rs. 208 Cr

Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth

JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24

JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year